Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Abingdon Health PLC ( (GB:ABDX) ) has provided an update.
Abingdon Health PLC announced that its subsidiary, CS (Lifesciences) Ltd, has secured a contract exceeding £500k with a major global diagnostics company for quality management systems and regulatory approvals. This contract, starting in March 2025, highlights the company’s enhanced service capabilities following its acquisition of CS (Lifesciences) Ltd in August 2024. The win underscores Abingdon Health’s strengthened market position and its ability to offer specialized expertise in the medical diagnostics sector, potentially benefiting stakeholders by expanding its client base and revenue streams.
More about Abingdon Health PLC
Abingdon Health PLC is a leading provider in the in vitro diagnostics (IVD) and med-tech industry, known for its comprehensive contract research (CRO) and contract development and manufacturing organization (CDMO) services. The company specializes in lateral flow product development and offers regulatory support services to international clients aiming to bring new assays to market. Abingdon also operates the Abingdon Simply Test range, an e-commerce platform for self-tests, and provides consultancy services for quality management and regulatory approvals.
YTD Price Performance: 3.23%
Average Trading Volume: 160,196
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £15.49M
See more data about ABDX stock on TipRanks’ Stock Analysis page.
